Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PSA pooh-poohed

This article was originally published in The Gray Sheet

Executive Summary

A task force sponsored by the Agency for Healthcare Research and Quality recommended that men 75 years or older should not undergo routine screening for prostate-specific antigen. The U.S. Preventative Services Task Force said Aug. 4 that it found "adequate evidence that the incremental benefits of treatment for prostate cancer detected by screening are small to none" for this population. For younger men, there was inadequate evidence to conclude whether or not routine PSA screening improved health outcomes
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT026446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel